ABT vs ADM Stock Comparison

Scores Breakdown

Metric	ABT	ADM
📈 Growth	18/30	26/30
💰 Profitability	17/20	16/20
🏦 Financial Health	18/20	18/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	4/10	7/10
Overall Score	71/100	77/100

Side-by-Side Summaries

ABT Analysis	ADM Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Over the 8 quarters, Revenues progressed from about $21.50B (2024 Q4) to $22.68B (2026 Q2), with a mid-period trough in 2025 Q4 near $18.56B. Net income rose from about $0.42B to roughly $0.91B by 2026 Q2, though 2025 saw a dip before the rebound. The 8-quarter trend shows growth, albeit choppy, culminating in a clear earnings acceleration on a year-over-year basis. 💰 Margins & Cash Flow Gross margin expanded from the mid single digits (roughly 6.4%–7%) to around 9% in 2026 Q1 and roughly 8.5% in 2026 Q2, signaling better product mix and leverage. Operating margin ran in the low-to-mid single digits, reflecting ongoing efficiency gains amid revenue volatility. Operating cash flow remained positive for most quarters; 2026 Q1 shows strong cash from operations, while 2026 Q2 recorded a net cash outflow driven by investing/financing activities. Investing cash flow remained negative as capex/activity persisted. 🛡️ Balance Sheet & Liquidity Assets of about $52–53B supported by equity around $22–23B and liabilities of roughly $29–30B, yielding solid leverage metrics. Current assets > current liabilities in most periods, with a healthy liquidity cushion and modest long-term debt (~$7.6B). ⚠️ Key Drivers & Risks Drivers: Demand in food/agri value chain; favorable margin trajectory from mix improvement and cost discipline. Risks: Commodity/price cycles and cyclicality; potential valuation sensitivity to commodity and macro shifts.

ABT Analysis

ADM Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Over the 8 quarters, Revenues progressed from about $21.50B (2024 Q4) to $22.68B (2026 Q2), with a mid-period trough in 2025 Q4 near $18.56B. Net income rose from about $0.42B to roughly $0.91B by 2026 Q2, though 2025 saw a dip before the rebound. The 8-quarter trend shows growth, albeit choppy, culminating in a clear earnings acceleration on a year-over-year basis.

💰 Margins & Cash Flow

Gross margin expanded from the mid single digits (roughly 6.4%–7%) to around 9% in 2026 Q1 and roughly 8.5% in 2026 Q2, signaling better product mix and leverage.
Operating margin ran in the low-to-mid single digits, reflecting ongoing efficiency gains amid revenue volatility.
Operating cash flow remained positive for most quarters; 2026 Q1 shows strong cash from operations, while 2026 Q2 recorded a net cash outflow driven by investing/financing activities. Investing cash flow remained negative as capex/activity persisted.

🛡️ Balance Sheet & Liquidity

Assets of about $52–53B supported by equity around $22–23B and liabilities of roughly $29–30B, yielding solid leverage metrics. Current assets > current liabilities in most periods, with a healthy liquidity cushion and modest long-term debt (~$7.6B).

⚠️ Key Drivers & Risks

Drivers: Demand in food/agri value chain; favorable margin trajectory from mix improvement and cost discipline.
Risks: Commodity/price cycles and cyclicality; potential valuation sensitivity to commodity and macro shifts.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"